The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines.
 
Dragan Cicic
Employment - Sellas Life Sciences; Sellas Life Sciences; Sellas Life Sciences
Leadership - Sellas Life Sciences
Stock and Other Ownership Interests - Sellas Life Sciences
Patents, Royalties, Other Intellectual Property - METHODS OF TREATING CANCER IN SUBJECTS HAVING AN ASXL1 MUTATION
Travel, Accommodations, Expenses - Sellas Life Sciences; Sellas Life Sciences
 
Angelos Stergiou
Employment - Sellas Life Sciences
Leadership - Cleara Biotech; Sellas Life Sciences
Stock and Other Ownership Interests - Cleara Biotech; Sella Life Sciences
Patents, Royalties, Other Intellectual Property - METHODS OF TREATING CANCER IN SUBJECTS HAVING AN ASXL1 MUTATION
Travel, Accommodations, Expenses - Cleara Biotech; Sella Life Sciences